What question did this study set out to answer?

The aim is to compare the effectiveness and safety of direct oral anticoagulants and low-molecular-weight heparin for treating venous thromboembolism in gastrointestinal cancer patients.

April 19, 2026Cancer Medicine0 citationsOpen Access

Direct Oral Anticoagulants Versus Low‐Molecular‐Weight Heparin for Treating Venous Thromboembolism in Patients With Gastrointestinal Cancer

View Full Paper

WCWei‐Ting ChangNational Sun Yat-sen University MLMei-Chuan LeeNational Cheng Kung University Hospital HLH W L LinNational Cheng Kung University Hospital

Key Points

The aim is to compare the effectiveness and safety of direct oral anticoagulants and low-molecular-weight heparin for treating venous thromboembolism in gastrointestinal cancer patients.
Compared the recurrence rates of VTE with DOACs and LMWH
Evaluated risks of intracranial hemorrhage and GI bleeding with each treatment
LMWH showed a lower risk of recurrent VTE compared to DOACs
DOACs had a lower risk of intracranial hemorrhage
DOACs presented a higher risk for gastrointestinal bleeding

Abstract

Compared with DOACs, LMWH expressed a lower risk of recurrent VTE in GI cancer patients. However, DOAC presented with a lower intracranial hemorrhage risk but a higher GI bleeding risk. Further research is needed to confirm these findings.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Direct Oral Anticoagulants Versus Low‐Molecular‐Weight Heparin for Treating Venous Thromboembolism in Patients With Gastrointestinal Cancer

Key Points

Abstract

Cite This Study

Also Consider

Also Consider